Autolus Therapeutics Business Summary

Autolus Therapeutics is a commercial-stage biopharmaceutical company specializing in next-generation programmed T-cell therapies. The company generates revenue primarily through the commercial sale of its lead CAR-T product, AUCATZYL (obecabtagene autoleucel), which is FDA-approved for adult relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). For the fiscal year 2026, Autolus has issued net product revenue guidance of $120 million to $135 million, marking its successful transition from a clinical-stage biotech to a commercial entity. The company operates across two primary segments: hematological oncology and an emerging portfolio in autoimmune diseases, including lupus nephritis. Within the competitive landscape, Autolus contends with major players such as Gilead Sciences (Kite), Novartis, and Bristol Myers Squibb. It distinguishes itself through its proprietary "fast-off" CD19 binding technology, which aims to minimize cytokine release syndrome (CRS) and neurotoxicity, positioning AUCATZYL as a safer alternative to first-generation therapies like Tecartus and Kymriah. Founded in 2014 as a spin-out from University College London (UCL), the company is built on the engineering innovations of Founder and Chief Scientific Officer Dr. Martin Pule. The leadership team is headed by Chief Executive Officer Dr. Christian Itin, who previously led Micromet through its acquisition by Amgen. Other key executives include Chief Financial Officer Rob Dolski, Chief Technology Officer Miranda Neville, and Chief Business Officer Dr. Chris Williams. Autolus is backed by high-profile strategic partners and investors, including Blackstone, which provided a $250 million financing deal, and BioNTech, which maintains a significant equity stake and strategic collaboration. The Board of Directors was further strengthened in late 2025 by the appointment of Ryan Richardson, former Chief Strategy Officer of BioNTech, reflecting the company’s focus on global commercial expansion and manufacturing scale-up.